From October 13-15, 2014, Nanogen Biopharmaceutical exhibited alongside 2,200 exhibitors from 140 countries with backgrounds in biotech and biotech-related industries, marking our fourth consecutive attendance at the highly regarded international conference.
Each year, Dr. Ho Nhan, our founder and CEO, emphasizes the importance of the event as it provides common grounds for catching up face-to-face with our esteemed customers and partners as well as opportunities to meet new ones.
Alongside Dr. Ho Nhan, Mr. Vipul Dholia, Head of International Business, and Mr. Jason Nguyen, Business Coordinator, were present to share about Nanogen’s latest and most exciting news.
First is the expansion of our manufacturing capacity and capabilities with the addition of a 6-story biosimilar manufacturing facility, housing some of the latest in biotech and packing machinery. The facility is targeted for EU-GMP and is expected to produce clinical quantities of our latest offerings before the end of 2015.
Next, we are excited to share about our latest pipeline products focused on anti-cancer monoclonal antibodies (mAb), such as Trastuzumab, Bevacizumab, and Rituximab, with some supporting therapies being developed in parallel. All of the listed treatments are planned for production in the new facility.
Nanogen would like to thank our partners and customers for taking the time to visit us at our booth at CPhI Worldwide in Paris, France and we are looking forward to seeing you again at CPhI Worldwide 2015 in Madrid, Spain!.
